Piper Sandler Reiterates Overweight Rating on Sutro Biopharma (STRO)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ORCL
2. SPY
3. SPCX
4. USO
5. CHWY
6. NAVN
7. HUMA
8. NVDA
9. CRWV
10. CME

Go back to Piper Sandler Reiterates Overweight Rating on Sutro Biopharma (STRO)

TD Cowen Reiterates Buy Rating on Sutro Biopharma (STRO)

September 16, 2024 9:11 AM UTC

TD Cowen analyst Tara Bancroft reiterated a Buy rating on Sutro Biopharma (NASDAQ: STRO).

The analyst commented, "Luvelta+bev's 35% ORR in an unselected population and multiple doses is impressive on its own given that Elahere+bev had a 44% ORR in higher... More